STOCK TITAN

Twist Bioscience CEO receives 95,351-share award

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Twist Bioscience Corp (TWST) CEO Emily M. Leproust reported an award of 95,351 common shares represented by performance stock units on November 12, 2026. After the award, she reported directly holding 653,538 common shares. The filing also lists two employee stock option positions: 131,290 shares at a $23.33 exercise price, expiring October 23, 2029, and 64,950 shares at $67.85, expiring August 31, 2030. Sixty percent of the PSUs remain subject to time-based vesting, scheduled for September 30, 2027, subject to continued service.

Insider Leproust Emily M.
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Common Stock F1 95,351 $0.00 $0.00
Holding Employee Stock Option (right to buy) F2 -- -- --
Holding Employee Stock Option (right to buy) F3 -- -- --
Holdings After Transaction: Common Stock — 653,538 shares (Direct); Employee Stock Option (right to buy) — 196,240 options (Direct)
Holdings Before and After: Common Stock, 558,187 to 653,538 shares (Direct)
Footnotes (3)
  1. F1. Represents Performance Stock Units for which target criteria was determined to have been met on November 12, 2026. 60% of the PSUs remain subject to time-based vesting and will vest on September 30, 2027, subject to continued service.
  2. F2. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
  3. F3. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Awarded common shares 95,351 shares Performance stock units reported November 12, 2026
Direct common shares following award 653,538 shares Reported after the November 12, 2026 award
Option underlying shares 131,290 shares Employee stock options at a $23.33 exercise price; expires October 23, 2029
Option exercise price $23.33 per share Option covering 131,290 underlying common shares; expires October 23, 2029
Option underlying shares 64,950 shares Employee stock options at a $67.85 exercise price; expires August 31, 2030
Option exercise price $67.85 per share Option covering 64,950 underlying common shares; expires August 31, 2030
PSUs subject to time-based vesting 60% Scheduled to vest September 30, 2027, subject to continued service
Performance Stock Units financial
"the award reported for November 12, 2026"
Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.
time-based vesting financial
"60% of the PSUs remain subject to time-based vesting"
Time-based vesting is a schedule that gives employees or contractors ownership of granted stock or options gradually as they remain with a company, like unlocking rewards in a loyalty program the longer you stick around. For investors, it matters because it affects future share supply, management incentives and staff retention — all of which can influence company performance and dilution of existing shareholders.
Employee Stock Option (right to buy) financial
"options covering underlying common shares"
performance stock options financial
"performance stock options granted on September 1, 2020"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did TWST CEO Emily M. Leproust report in her award?

Emily M. Leproust reported an award of 95,351 common shares represented by performance stock units on November 12, 2026. Sixty percent remain subject to time-based vesting and are scheduled to vest on September 30, 2027, subject to continued service.

What vesting schedule applies to one of TWST CEO Emily M. Leproust's stock options?

For the option covering 131,290 common shares, 25% vested on October 24, 2020, and 1/48th vested on each monthly anniversary thereafter, subject to Emily M. Leproust's continuous service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Leproust Emily M.

(Last)(First)(Middle)
C/O TWIST BIOSCIENCE CORPORATION
681 GATEWAY BLVD.

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/12/2026A95,351(1)A$0653,538D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)$23.33 (2)10/23/2029Common Stock131,290131,290D
Employee Stock Option (right to buy)$67.8512/19/202208/31/2030Common Stock64,95064,950(3)D
Explanation of Responses:
1. Represents Performance Stock Units for which target criteria was determined to have been met on November 12, 2026. 60% of the PSUs remain subject to time-based vesting and will vest on September 30, 2027, subject to continued service.
2. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
3. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Remarks:
/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading